Stockscreener 앱 받기
1.12
1.75%
-0.02
시간 외 거래:
1.17
0.05
+4.46%
Fractyl Health Inc 주식(GUTS)의 최신 뉴스
Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025 - Insider Monkey
10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Fractyl Health Reports Positive Early Data Showing Revita® - GlobeNewswire
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation - The Manila Times
Revolutionary Device Cuts Post-GLP-1 Weight Regain by 60% in Breakthrough Study - Stock Titan
Fractyl Health, Inc. (NASDAQ:GUTS) Shares Acquired by Bank of New York Mellon Corp - Defense World
Fractyl Health director Barnes acquires $40,210 in common stock - Investing.com India
Fractyl Health director Ajay Royan purchases $22,979 in common stock By Investing.com - Investing.com Australia
Fractyl Health director Ajay Royan purchases $22,979 in common stock - Investing.com India
FRACTYL HEALTH Executives Increase Their Stakes - TradingView
Fractyl Health director Barnes acquires $40,210 in common stock By Investing.com - Investing.com UK
FRACTYL HEALTH Director Bradley William Acquires 16,129 Shares - TradingView
Fractyl Health sets June 11 for 2025 stockholder meeting - Investing.com
Fractyl Health sets June 11 for 2025 stockholder meeting By Investing.com - Investing.com South Africa
Rhumbline Advisers Boosts Stock Holdings in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Spotlight On Fractyl Health And Two Other Intriguing Penny Stocks - Yahoo Finance
Fractyl Health Reports 2024 Financial Results and Strategic Progress - MSN
Earnings call transcript: Fractyl Health’s Q4 2024 results miss expectations, stock drops - Investing.com India
FRACTYL HEALTH Earnings Results: $GUTS Reports Quarterly Earnings - Nasdaq
Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates - TradingView
Fractyl Health Highlights Urgent Demand for Weight Maintenance Solutions Post-GLP-1 Therapy in Upcoming REMAIN-1 Study Amid Strategic Focus on Metabolic Health - Nasdaq
Fractyl's Weight Maintenance Study Hits 189 Patients: Can It Solve the GLP-1 Rebound Problem? - StockTitan
Earnings Scheduled For March 3, 2025 - Benzinga
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025 - The Manila Times
Fractyl Health to Report Fourth Quarter and Full Year 2024 - GlobeNewswire
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide ... - The Bakersfield Californian
Can This Metabolic Disease Pioneer Deliver Strong Q4 Results? Fractyl Health Reports March 3 - StockTitan
Fractyl Health, Inc. (NASDAQ:GUTS) Sees Significant Drop in Short Interest - MarketBeat
Stratos Wealth Partners LTD. Sells 21,148 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS) - Yahoo Finance
Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments - PharmaVoice
Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) CEO Sells 90,972 Shares of Stock - MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Fractyl Health (NASDAQ:GUTS) Price Target Cut to $10.00 by Analysts at Morgan Stanley - MarketBeat
Potential Price Increase for Fractyl Health Inc (GUTS) After Recent Insider Activity - Knox Daily
BlackRock, Inc. Increases Stake in Fractyl Health Inc: A Strategic Move in Biotechnology - GuruFocus.com
Fractyl Health, Inc. (NASDAQ:GUTS) Stock Position Lifted by JPMorgan Chase & Co. - Defense World
Fractyl Health, Inc. (NASDAQ:GUTS) Insider Jay David Caplan Sells 22,346 Shares - MarketBeat
Fractyl Health Inc (GUTS) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Trading Day Triumph: Fractyl Health Inc (GUTS) Ends at 1.70, a -7.61 Surge/Plunge - The Dwinnex
Fractyl Health (NASDAQ:GUTS) Given New $10.00 Price Target at Morgan Stanley - Defense World
FRACTYL HEALTH Executives Sell Shares - TradingView
Fractyl Health announces layoffs as it pivots to gene therapy - Mass Device
Burlington biotech company announces layoffs, pivots research focus - NBC Boston
Fractyl Health Announces Increased Focus on Groundbreaking - GlobeNewswire
Fractyl Health pivots Type 2 diabetes device therapy toward obesity and GLP-1s, lays off 17% of staff - Fierce Biotech
Fractyl Health To Focus On Revita, Rejuva Programs, To Cut Workforce By 17%; Stock Down - Nasdaq
Fractyl Health announces increased focus on Revita, Rejuva programs - TipRanks
Fractyl Health Reprioritizes Focus on REMAIN-1 Study - TipRanks
Fractyl Health Prioritizes Clinical Development of Revita and Advances Rejuva Gene Therapy in Response to Market Demand - Nasdaq
3.01%
자본화:
|
볼륨(24시간):